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Abstract: (1) Objective: to establish practical guidance for the design of future clinical trials in MS
(metabolic syndrome) patients aged 18 and older, based on a systematic review of randomized
clinical trials connecting diet, physical exercise and changes in body composition. (2) Method: this
systematic review of randomized clinical trials (RCT) is based on the guidelines recommended by
PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses). Criteria of selection:
≥18 years of age; patients diagnosed with MS; intervention programs including diet, physical exercise
and/or modifications in the style of life as treatment, as well as the magnitude of changes in body
composition (BC); randomized clinical trial published between 2004 and 2018. (3) Results: the
multidisciplinary interventions describe major changes in BC, and the recurring pattern in these
clinical trials is an energy reduction and control in the percentage of intake of macronutrients along
with the performance of regularly structured exercise; the most analyzed parameter was waist
circumference (88.9% of the trials), followed by body weight (85.2%), BMI (77.8%) and body fat
(55.6%). (4) Conclusions: The analysis of the information here reported sheds light for the design of
future clinical trials in adults with MS. The best anthropometric parameters and units of measurement
to monitor the interventions are related to dietary and physical exercise interventions. A list of
practical advice that is easy to implement in daily practice in consultation is here proposed in order to
guarantee the best results in changes of body composition.
Keywords: metabolic syndrome; diabetes; diet; exercise; body composition; weight and fat
1. Introduction
1.1. Metabolic Syndrome (MS): Concept, Prevalence and Diagnostic Criteria
MS was firstly described in 1920 by Kylin, a Swedish physician, as a connection between
hypertension, hyperglycemia and gout. Later, in 1947, Vague indicated that visceral obesity is commonly
associated with metabolic alterations, mentioning cardiovascular diseases and type 2 diabetes mellitus
(T2DM) as the key pathologies. Then in 1965, at the annual meeting of the European Association for the
Study of Diabetes, MS was described as a syndrome related to hypertension, hyperglycemia and obesity.
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In 1989, Kaplan linked the syndrome to the combination of upper-body obesity, glucose intolerance,
hypertriglyceridemia and hypertension. However, in 1998, a WHO diabetes research group defined
MS as a group of interconnected physiological, biochemical, clinical and metabolic factors that directly
increase the risk of cardiovascular disease, T2DM and all-cause mortality [1]. The MS is also known
as “insulin resistance syndrome”, “quartet of death” or “syndrome X” [2], thus including abdominal
obesity, prehypertension or hypertension, dyslipidemia and prediabetes [3]. Useful definitions for the
readers to distinguish between diabetes, prediabetes, insulin resistance, etc. can be found in the review
of the American Diabetes Association [4].
This syndrome affects to more than 20% of the adult population of the United States, China,
Europe and the developed countries. This prevalence increases with age in a specific correlation
with sex: before the age of 50 years, men have a higher prevalence and after 50 years, this trend is
reversed [5–7]. There are up to five types of diagnostic criteria to identify MS [1,8], consequently
the lack of unification in the universally accepted diagnostic criteria makes it difficult to determine
the prevalence of MS [9,10]. Thus, the diagnostic criteria of the MS change depending on the age
(few criteria exist for MS diagnosis of children, teenagers and adults) and the continent [1,8,11].
1.2. MS: Causes, Diet, Exercise and Anthropometric Parameters
The main factors promoting MS and consequently T2DM are: excess ingestion of nutrients,
low physical activity and the production of inflammatory cytokines [12–16]. As an example, in an
investigation including 61,239 men and 73,216 women (40–74 years of age) from Shanghai (China), it
was observed that with major fulfilment of the dietetic directives, minor mortality was detected [17].
The increase of physical exercise is the best non-pharmacological treatment for obesity, as it can
reduce insulin resistance, to counteract the inflammatory state and to improve the lipid profile [7,18].
Changes of the following anthropometrical parameters could contribute to the improvement of health
in MS patients: fat mass index (fat mass·height−2), waist circumference, abdominal diameter and
corporal weight [19–22].
This systematic review is justified by the following facts:
1. The high rates of MS worldwide and the lack of consensus in the criteria used for MS diagnosis
make difficult to determine MS prevalence [1,8].
2. Dietary and physical exercise interventions are both causative and controlling tools for eliminating
MS risk factors and the emergence of T2DM [11–15]. Thus, it is important to analyze the
characteristics of the interventions causing the greatest changes [19–22].
The main objective of this systematic review was to establish practical guidance for the design of
future clinical trials in MS patients aged 18 and older, based on a systematic review of randomized
clinical trials connecting diet, physical exercise and changes in body composition. Other secondary
objectives related to MS have also been analyzed: (a) to record which interventions (exclusive or
multidisciplinary interventions) produce the greatest changes in body composition in MS patients
≥18 years of age; (b) to identify which are the dietetic and physical exercise patterns showing the
most significant changes in corporal composition in MS patients ≥18 years of age, in order to stablish
accurate clinical trials in the next future; (c) to identify the most used anthropometric parameters
and units of measure to record the changes in body composition, in MS patients ≥18 years old; (d) to
analyze dietary and physical exercise patterns proposed by guidelines for intervention in overweight,
obesity, diabetes and MS patients ≥18 years of age.
2. Materials and Methods
2.1. Search Strategy and Information Processing
This systematic review of randomized clinical trials is based on the guidelines recommended by
PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) [23]. The information
retrieval system “Boolean” was used to identify the works of interest for this review [24].
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All the data used in this study were obtained from the following databases: CINAHL
(Current Nursing and Allied Health Literature), ProQuest (which supplies services of information
for universities, schools, public companies, corporations and public libraries worldwide), PubMed
(a search engine for free access to the MEDLINE database of citations and abstracts of biomedical
research articles) and Web of Science (online scientific information service, provided by Thomson
Reuters, integrated in ISI Web of Knowledge, WOK, containing original articles based on clinical
trials). The keywords used were: “MS” “weight loss”, “fat loss”, “diet”, “exercise” and “lifestyle”.
These keywords were obtained from the “MeSH database” (Medical Subject Heading) and NLM
(The National Library of Medicine). Controlled vocabulary thesaurus was used for indexing articles for
PubMed. The search strategies used are displayed in Table 1. To identify and to select the information
obtained from databases, the following filters were used: date of publication between January 2004 and
December 2018. Other additional settings from each specific database were fixed: “CINAHL” database,
“AB Summary” and “academic publications”; “ProQuest” database, advanced search including the
options “evaluated by experts”, “scientific magazines”, “article” and “abstract”; “PubMed” database,
advanced search including the options “Title/Abstract” and “clinical trial”; “Web of Science” database,
basic search selecting the options “theme”, “article” and “clinical trial”. The starting open research
questions were as follows. What interventions produce the greatest changes in body composition in
MS patients ≥ 18 years of age? What dietetic and physical exercise patterns show the most significant
changes in corporal composition? What are the most used anthropometric parameters and units of
measure to record the changes in body composition? Is it possible to propose more accurate practical
guidance in order to promote more significant changes in body composition?
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Table 1. Search strategies used to identify and select clinical trials, dates: 2004–2018.
Search Strategy CINAHL Identified/Included ProQuest Identified/Included PubMed Identified/Included Web of Science Identified/Included
“metabolic syndrome” AND “weight
loss” OR “weight reduction” OR “fat
loss” OR “fat reduction” OR “lifestyle”
AND “exercise” OR “physical activity”
OR “sport” OR “weightlifting”
222/5 532/7 187/22 303/29
“metabolic syndrome” AND “weight
loss” OR “weight reduction” OR “fat
loss” OR “fat reduction” OR “lifestyle”
AND “diet” OR “dietary treatment”
AND “feeding” OR “nutrition” OR
“nutritional counselling”
27/1 87/2 18/2 149/6
“type II diabetes” OR “insulin resistance”
AND “weight ls” OR “weight reduction”
OR “fat loss” OR “fat reduction” AND
“diet” OR “dietary treatment” OR
“feeding” AND “nutrition” OR
“nutritional counselling” OR “lifestyle”
44/0 77/0 42/2 155/3
“type II diabetes” OR “insulin resistance”
AND “weight loss” OR “weight
reduction” OR “fat loss” OR “fat
reduction” AND “exercise” OR “physical
activity” OR “sport” OR “weightlifting”
119/1 231/3 152/4 339/5
Articles or clinical trials identified: complete list of articles retrieved from various databases (PubMed, Web of Science, etc.), without having made the selection of the clinical trials of
interest. Articles or clinical trials included: articles that meet the selection criteria.
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2.2. Selection of the Articles Previously Identify
Each of the identified articles were independently analyzed by three researchers. PICOS strategy
was used to define the eligibility criteria for this review (population, intervention, comparisons, results
and characteristics of clinical trials):
Different criteria included in the search strategy were: age of the patients ≥18 years [25]; patients
with MS [1,8]; intervention programs including diet, physical exercise and/or modifications in the
style of life as treatment as well as the magnitude of changes in body composition; randomized
clinical trial published between 2004 and 2018 in scientific journals in Spanish and English (Figure 1).
The two languages were selected due to their impact and use at global scale (English is in general
the “lingua franca” for communicating science. Besides, English and Spanish are two of three
most spoken languages worldwide (https://danivoiceovers.com/en/los-10-idiomas-mas-hablados-
mundo/; https://www.europapress.es/sociedad/noticia-idiomas-cifras-cuantas-lenguas-hay-mundo-
20190221115202.html). The articles finally selected summarized details about the changes in body
composition through the anthropometric parameters and units of measure (Tables 2 and 3) [26–62].
A total amount of 2684 articles were discarded due to the following exclusion criteria: they
include one, or part of the main subjects considered for this review (MS, T2DM or insulin resistance)
(1647 articles, 61.4%); diet and/or physical exercise are not included for weight loss (13 articles, 0.48%);
they are not a clinical trial, with different interventions and their comparison (589 articles, 21.94%);
they are not randomized clinical trials (six articles, 0.22%); the decrease of body weight, BMI, body fat
or waist circumference are not analyzed at least before and after the intervention (57 articles, 2.21%);
they include in the sample patients under 18 years of age (253 articles, 9.43%); studies carried out
with animal models instead of human beings (27 articles; 1.01%); clinical trials repeated (55 articles;
2.05%) (Figure 1) [23]. Besides, it was also necessary to discard two intervention groups from two
independent clinical trials, because other methods of changes in body composition such as the gastric
ball and supplementation were included as a subsection of intervention (Table 3) [48,59].
Data were extracted from the following five domains [23] (Tables 2 and 3):
1. Population: characteristics of the population studied (country of origin, type of diagnostic criteria,
number, age and gender), inclusion and exclusion criteria.
2. Interventions: exclusive and multidisciplinary as therapeutic treatments.
3. Comparators: inclusion of randomized clinical trials, control and intervention groups are
identified. In principle, only the intervention groups receive the therapeutic treatment that should
cause changes in body composition.
4. Results: identified as variation in body composition, presenting significant and not
significant variations.
5. Characteristics of clinical trials: authors, year of publication, type of randomized clinical trial,
duration of intervention, instrument of analysis of body composition, type of intervention
used (exclusive or multidisciplinary) and body composition variation (measured with different
anthropometric parameters and units of measurement).
2.3. Data Analysis, Identification of Information Loss Risks
All the essential information required to carry out this systematic review is summarized in a
total of six tables, a flowchart and a figure. The flowchart and Table 1 display the details of the search
strategies and databases used; Tables 2 and 3 display the relevant details of the interventions recorded
including the following items: title, author(s), type of sample/group, duration of the intervention, type
of method/intervention, variation of the anthropometric parameters and units of measurement (this
variation was registered using the following parameters): body weight (BW) in kg; body fat (BF) in kg
or %; body mass index (BMI) in kg/m2 and waist circumference (WC) in cm, or their respective drop in
percentage (%) in each parameter. To identify the variation of these parameters and units, a Yes/No
code has been used: YES means that the article includes the study of the parameters in the respective
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standard units, and NO means that the article does not include the parameters in their study. Thus,
the most significant changes in body composition from each clinical trial was registered based on each
parameter and unit (Tables 2 and 3).
The searches were made independently (one for each of the authors). The other tables were
performed jointly.
Heterogeneity of the clinical trials design has been the major limitation in this research. Only few
articles present adequate data to calculate heterogeneity statistics, but the contrasts done in this sense
with the analyzed works reported, in general, a lack of homogeneity.
In order to analyze the quality in the design of clinical trials included in this work involving
the highest variations in body composition, the Consort method has been used (assessment and
implementation guide on the most appropriate guidelines for the design of randomized trials).
Negative results should be considered for items that have not been performed or have been performed
in an incomplete way, and positive results are those in which the items were fulfilled entirely [63].
The results of this analysis have been summarized with the calculation of the percentage of negative
results compared to the totality of analyzed items. The designs in this review indicate low positive
results so this would be one of the limitations of this research.
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Figure 1. Flow chart in the screening process for the selection of included clinical trials [23].
Legend exclusion criteria: 1. they include one, or part of the main subjects considered for this
review (MS, T2DM or insulin resistance); 2. diet and/or physical exercise are not included for weight
loss; 3. They are not clinical trials, with different interventions and their comparison; 4. not being a
randomized clinical trial; 5. the decrease of body weight, BMI, body fat or waist circumference are not
analyzed at least before and after the intervention; 6. they include in the sample patients under 18
years of age; 7. studies carried out with animal models instead of human beings.
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Table 2. Characteristics of the randomized trials included in the reduction of body composition in metabolic syndrome: exclusive interventions.
Author (s)
[26–35] Location
Study
Design
MS Diagnosis
Criteria [1]
Sample/Groups/
Characteristics Studied
Duration
(Months)
Body Composition
Measurement Instrument
Intervention Method
Characteristics
Studied/Comparative Statistical
Analysis of BC
Anthropometric Parameters and Measurement
Unit Analyzed (Statistical Results) Decreases in Body Composition
Mean ± SD or Mean ± (SE) or
Mean (CI, 95%)BW (kg/%)
BF
(kg or %)
BMI
(kg/m2/%)
WC
(cm/%)
[26] Asia(Iran) RCT ATPIII
n = 87
IG1: 43
IG2: 44
Women: 60.95%
Age: 45.5
2.5
Body composition indices
were measured via
bioelectric impedance
analysis (BIA; In Body s10;
Korea). Height was
measured bar using
a stadiometer
Diet
- Within groups:
IG1: low fat plain
yogurt
IG2: fortified yogurt
- Between groups
YES/NO
p < 0.001
p < 0.001
NS
YES/YES
p < 0.0001
p < 0.05
p < 0.05
YES/NO
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
p < 0.05
BW:
IG1: 4.3 ± 1.9 kg
IG2: 5.1 ± 3.0 kg
BF:
IG1: 1.7 ± 2.4 kg and 1.7 ± 3.2%
IG2: 3.4 ± 4.7 kg and 3.0 ± 2.8%
BMI:
IG1: 1.6± 0.1 kg
IG2: 1.8 ± 1.16 kg
WC:
IG1: 4.4 ± 1.7 cm
IG2: 5.8 ± 2.0 cm
[27] Asia(Israel)
RCT
(parallel-arm) ATPIII
n = 74
IG1: 38
IG2: 36
Women: 100%
Age: 30–57
3
BW and WC were measured
by using a scale model
Detector Physician Beam
Scale (HOSPEQ, Inc., Miami,
FL) vs. the same person
according to the guidelines
of the National Heart, Lung,
and Blood
Institute respectively
Diet- Within groups:
IG1 (high breakfast kcal content)
IG2 (high dinner kcal content)
- Between groups
YES/NO
p < 0.0001
p < 0.05
p < 0.0001
NO/NO YES/NO
p < 0.0001
p < 0.05
p < 0.0001
YES/NO
p < 0.0001
p < 0.05
p < 0.0001
BW:
IG1: 8.7 ± (1.4) kg
IG2: 3.6 ± (1.5) kg
BMI:
IG1: 3.1± (0.4) kg/m2
IG2: 1.3± (0.4) kg/m2
WC:
IG1: 8.7 ± (0.9) cm
IG2: 3.6 ± (0.9) cm
[28] Europe(Spain)
RCT
(parallel-group) ATP III
n = 50
IG1: 25
IG2: 25
Men (56%)
Age: 18–65
3
Height and BC was
measured using a
wall-mounted stadiometer
vs. Tanita TBF-300 (Tanita
Corp., Tokyo, Japan)
bioimpedance analysis
device respectively
Diet
- Within groups:
IG1 (nut diet)
IG2
- Between groups
YES/NO
p < 0.05
p < 0.05
NS
YES
(%)/NO
p < 0.05
p < 0.05
NS
NO/NO YES/NO
p < 0.05
p < 0.05
NS
BW:
IG1: 2.2 kg
(0.9–3.4)
IG2: 1.5 kg
(0.6–2.4)
BF:
IG1: 1.9% (0.9–2.5)
IG2: 1.1% (0.3–1.9)
WC:
IG1: 3.8 cm
(1.9–5.8)
IG2: 2.7 cm
(1.0–4.4)
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Table 2. Cont.
Author (s)
[26–35] Location
Study
Design
MS Diagnosis
Criteria [1]
Sample/Groups/
Characteristics Studied
Duration
(Months)
Body Composition
Measurement Instrument
Intervention Method
Characteristics
Studied/Comparative Statistical
Analysis of BC
Anthropometric Parameters and Measurement
Unit Analyzed (Statistical Results) Decreases in Body Composition
Mean ± SD or Mean ± (SE) or
Mean (CI, 95%)BW (kg/%)
BF
(kg or %)
BMI
(kg/m2/%)
WC
(cm/%)
[29] Europe(Italy) RCT ATP III
n = 100
IG1: 50
IG2: 50
Women: 73%
Age: >18
5
Height was measured using
a stadiometer and WC, to the
measurement of the
narrowest circumference
between the bottom of the
rib cage and the iliac crest by
using an unstretched
tape measure
Diet
- Within groups:
IG1 (high CH diet)
IG2 (low CH diet)
- Between groups
YES/YES
p < 0.001
p < 0.001
NS
NO/NO YES/NO
p < 0.001
p < 0.001
NS
YES/YES
p < 0.001
p < 0.001
NS
BW:
IG1: NE (kg)
IG1: 10%
IG2: NE (kg)
IG2: 10%
BMI:
IG1: NE
IG2: NE
WC:
IG1: NE (cm)
IG1: 8%
IG2: NE (cm)
IG2: %
[30] Europe(Spain)
RCT
(Randomized-block) IDF
n = 160
IG: 138
CG: 22
Women: 50%
Age: 54 ± 8
4
Body weight was assessed in
an electronic scale (Hawk,
Mettler Toledo, USA) body
composition was determined
by dual energy X-ray
absorptiometry (DXA
Hologic Series Discovery Wi
QDR, Bedford, USA). WC
was measured in a
horizontal plane 2 cm above
the iliac crest
Exercise
Within groups:
IG: aerobic interval training
CG: sedentary
Between groups
YES/NO
p < 0.05
NE
p < 0.05
YES/NO
NS
NE
NS
YES/NO
p < 0.05
NE
p < 0.05
YES/NO
p < 0.05
NE
p < 0.05
BW:
IG: 1.2 kg
CG: increase
BF:
IG: 0.7 kg
CG: increase
BMI:
IG: 0.4 kg
CG: increase
WC:
IG: 2.6 cm
CG: increase
[31]
North
America
(USA)
RCT IDF
n = 34
CG: 10
IG1:13
IG2: 11
Women: 75%
Age: 49.1 ± 1.8
4
Air displacement
plethysmography (Bod-Pod;
Life Measurement
Instruments, Concord, CA)
Exercise
- Within groups:
IG1 (low intensity exercise)
IG2 (high intensity)
- Between groups
YES/NO
p < 0.01
p < 0.01
NS
YES
(%)/NO
p < 0.01
p < 0.01
NS
YES/NO
p < 0.01
p < 0.01
NS
YES/NO
NS
p < 0.01
NS
BW:
IG1: 2.7 kg
IG2: 2.7 kg
BF:
IG1: 0.7%
IG2: 1.6%
BMI:
IG1: 0.9 kg/m2
IG2: 0.9 kg/m2
WC:
IG1: 2 cm
IG2: 4.9 cm
[32]
North
America
(USA)
RCT IDF
n = 27
CG: 7
IG1: 11
IG2: 9
Women: 100%
Age: 51 ± 9
4
Air displacement
plethysmography (Bod-Pod,
Life Measurement
Instruments, Concord, CA)
Exercise
- Within groups:
IG1 (low-intensity aerobic)
IG2 (moderate-to-high intensity
aerobic)
- Between groups:
IG1 vs. IG2
IG1 vs. CG
IG2 vs. CG
YES/NO
NS
p < 0.05
NS
NS
NS
YES
(%)/NO
NS
p < 0.05
NS
NS
NS
YES/NO
NS
p < 0.05
NS
NS
NS
YES/NO
NS
p < 0.05
p < 0.05
NS
p < 0.05
BW:
IG1: 2.1 kg
IG2: 3.5 kg
BF:
IG1: 0.4%
IG2: 1.7%
BMI:
IG1: 0.8 kg/m2
IG2: 1.3 kg/m2
WC:
IG1: 1.2 cm
IG2: 5.6 cm
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Table 2. Cont.
Author (s)
[26–35] Location
Study
Design
MS Diagnosis
Criteria [1]
Sample/Groups/
Characteristics Studied
Duration
(Months)
Body Composition
Measurement Instrument
Intervention Method
Characteristics
Studied/Comparative Statistical
Analysis of BC
Anthropometric Parameters and Measurement
Unit Analyzed (Statistical Results) Decreases in Body Composition
Mean ± SD or Mean ± (SE) or
Mean (CI, 95%)BW (kg/%)
BF
(kg or %)
BMI
(kg/m2/%)
WC
(cm/%)
[33] Asia(China) RCT IDF
n = 173
IG: 86
CG: 87
Women: 50.8%
Age: 24–78
3 NE
Intervention in lifestyle
- Within groups:
IG (Lifestyle intervention
program)
- Between groups
YES/NO
NE
p < 0.01
NO/NO YES/NO
NE
p < 0.01
YES/NO
NE
NS
BW:
IG: 1.77 kg
CG: increase
BMI:
IG: 0.58 kg/m2
CG: 0.01 kg/m2
WC:
IG: 3.69 (male)/1.37 (female)
CG: 1.61 (male)/1.34 (female)
[34]
North
America
(USA)
RCT IDF
n = 135
IG1: 72
IG2: 63
Women: 75%
Age: 52
24
The International Diabetes
Federation definition
requires central obesity,
measured by WC with
ethnicity-based cutoffs
Intervention in lifestyle
- Within groups:
IG1 (individual counselling)
IG2 (group counselling)
- Between groups
YES/YES
p < 0.05
p < 0.05
p < 0.001
NO/NO YES/NO
p < 0.001
p < 0.05
p < 0.05
YES/NO
p < 0.05
p < 0.05
NS
BW:
IG1: 2.2 ± 14.2 kg
IG1: 1.8 ± 18.6%
IG2: 6.2 ± 14.3 kg
IG2: 5.6 ± 26.8%
BMI:
IG1: 0.8 kg/m2
IG2: 2.1 kg/m2
WC:
IG1: 2.4 ± 15.5 cm
IG2: 3.1 ± 15.5 cm
[35] Asia(East Asia) RCT
The Examination
Committee of
Criteria
for “Metabolic
Syndrome” in Japan
n = 102
IG:49
CG:53
Men: 100%
Age: 53.2 ± 6.8
6
Body height and body
weight were measured using
an automated scale
(AD-6225A; A&D,
Tokyo, Japan)
Intervention in lifestyle
CG (standard healthy
recommendations)
- Within groups:
IG (intervention in lifestyle)
- Between groups
YES/NO
p < 0.001
p < 0.001
NO/NO YES/NO
p < 0.001
p < 0.01
YES/NO
p < 0.001
p < 0.05
BW:
IG: 2.01 kg
BMI:
IG: 0.6 kg/m2
WC:
IG: 2.51 cm
Body weight (BW); body fat (BF); body mass index (BMI); waist circumference (WC); control group (CG); intervention group (IG); carbohydrates (CH); non-significant (NS); the information
is not available in the clinical trial evaluated (NE); randomized controlled trial (RCT); YES: the article includes the analysis of the parameter expressed in its correspondent units; NO: the
article does not include the analysis of the parameter.
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Table 3. Characteristics of the randomized trials included in the reduction of body composition in metabolic syndrome: multidisciplinary interventions.
Author(s)
[36–62]
Location Study
Design
MS Diagnosis
Criteria [1]
Sample/Groups/
Characteristics Studied
Duration
(months)
Body Composition
Measurement Instrument
Intervention
Method/Comparative Statistical
Analysis of the BC
Anthropometric Parameters and Measurement Unit
Analyzed (Statistical results) Decreases in Body Composition
Mean ± SD or Mean ± (SE) or
Mean (CI, 95%)BW (kg/%) BF (kg or %) BMI(kg/m2/%)
WC
(cm/%)
[36]
North
America
(USA)
RCT NE
n = 39
IG1:23
IG2:16
Women: 60%
Age: 38–76
6 NE
Diet, exercise
- Within groups:
IG1 (hypocaloric diet + MUFA)
IG2 (hypocaloric diet + PUFA)
- Between groups
YES/NO
NS
p < 0.01
NE
NO/NO NO/NO NO/NO
BW:
IG1: 2.3 kg ± (1)
IG2: 4.6 kg ± (2)
[37] Europe(Spain) RCT NE
n = 36
CG: 12
IG1:12
IG2: 12
Men: 75%
Age: 54 ± 9
4
Dual Energy X-ray
absorptiometry scans
(Hologic Discovery DXA
Series Wi QDR,
Bedford, USA)
Diet, exercise
- Within groups:
IG1 (EXER-then-DIET)
IG2 (EXER+DIET)
- Between groups:
IG1 vs. CG
IG2 vs. CG
IG2 vs. IG1
YES/YES
NS
p < 0.05
NE
NE
NE
YES/NO
NS
p < 0.05
NE
NE
NE
YES/NO
NS
p < 0.05
NE
NE
NE
YES/NO
p < 0.05
p < 0.05
NS
p < 0.05
NS
BW:
IG1: NE kg
IG1: NE%
IG2: NE kg
IG2: 5.5 ± 0.8%
BF:
IG1: NE (kg)
IG2: NE (kg)
BMI:
IG1: increase
IG2: 1.8 kg/m2
WC:
IG1: NE (cm)
IG2: NE (cm)
[38] Oceania(Australia) RCT ATPIII
n = 62
IG1: 21
IG2: 20
IG3: 21
Women: 55%
Age: 30–60
6
The participants weighing <
157 kg was measured with
Hologic DXA (QDR-4500W;
Hologic Corporation), and
those weighing > 157 kg
were measured with a GE
Lunar iDXA
(General Electric)
Diet, exercise
- Within groups:
IG1 (M-DASH diet)
IG2 (BOLD diet)
IG3 (BOLD + diet)
- Between groups
YES/NO
p < 0.001
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
p < 0.001
NS
BW:
IG1: 5.1 kg
IG2: 4.8 kg
IG3: 4.8 kg
BF: NE
BMI:
IG1: 1.8 kg/m2
IG2: 0.5 kg/m2
IG2: 1.7 kg/m2
WC:
IG1: 5.5 cm
IG2: 7.6 cm
IG3: 6.2 cm
[39] Europe(Spain) RCT ATP III
n = 36
IG1: 8
IG2: 8
IG3: 10
IG4: 10
Women and Men: NE
Age: 50–70
3
The anthropometric study
stated by the International
Society for the Advancement
of Kit anthropometry
(method ISAK); to evaluate
BW and height rods were
used (MB 201T Bonus); the
cutaneous folds were valued
by means of the
Harpenden calibrator
Diet, exercise
Within groups:
IG1 (Hypocaloric Med diet)
IG2 (Low fat-high CH diet)
IG3 (Hypocaloric Med diet and
exercise)
IG4 (Low fat-high diet and
exercise)
- Between groups:
IG2 vs. IG1
IG2 vs. IG3
IG2 vs. IG4
IG4 vs. IG1
IG4 vs. IG3
NO/YES
NS
p < 0.05
NS
p < 0.05
p < 0.05
p < 0.05
p < 0.05
p < 0.05
p < 0.05
NO/YES
p < 0.05
p < 0.05
p < 0.05
p < 0.05
p < 0.05
p < 0.05
p < 0.05
p < 0.05
p < 0.05
NO/NO NO/NO
BW:
IG1: ~ 7%
IG2: ~ 8%
IG3: ~ 5%
IG4: ~ 10%
BF:
IG1: ~ 7%
IG2: ~ 10%
IG3: ~ 9%
IG4: ~ 12%
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Table 3. Cont.
Author(s)
[36–62]
Location Study
Design
MS Diagnosis
Criteria [1]
Sample/Groups/
Characteristics Studied
Duration
(months)
Body Composition
Measurement Instrument
Intervention
Method/Comparative Statistical
Analysis of the BC
Anthropometric Parameters and Measurement Unit
Analyzed (Statistical results) Decreases in Body Composition
Mean ± SD or Mean ± (SE) or
Mean (CI, 95%)BW (kg/%) BF (kg or %) BMI(kg/m2/%)
WC
(cm/%)
[40] Europe(Austria) RCT ATPIII
n = 71
IG1: 36
IG2: 35
Men: 100%
Age: 36–66
0.75 NE
Diet, exercise
- Within groups:
IG1 (moderate altitude exercise)
IG2 (sea level exercise)
- Between groups
YES/NO
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
NE
YES/NO
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
NE
BW:
IG1: 3.22 ± 1.91 kg
IG2: 3.04 ± 2.16 kg
BF: NE
BMI:
IG1: 0.81 kg/m2
IG2: 0.69 kg/m2
WC: NE
[41] Europe(France) RCT OMS
n = 78
IG1: 24
IG2: 24
IG3: 30
Women: 56%
Age: 50–70
12 DXA (Hologic QDR 4500series; Waltham, USA)
Diet, exercise
- Within groups: IG1
(moderate-resistance and
moderate-endurance) IG2
(high-resistance and
moderate-endurance) IG3
(moderate-resistance and
high-endurance)
- Between groups
NO/YES
p < 0.001
p < 0.001
p < 0.001
NS
NO/YES
p < 0.001
p < 0.001
p < 0.001
NS
NO/NO NO/YES
p < 0.001
p < 0.001
p < 0.001
NS
BW:
All: 6.3 ± 7.2%
IG1: 5.9 ± 5.8%
IG2: 8.4 ± 8.9%
IG3: 4.7 ± 6.7%
BF:
All: 1.7 ± 1.7%
IG1: 1.8 ± 1.5%
IG2: 2.1 ± 2.3%
IG3: 1.3 ± 1.3%
WC:
All: 7.7 ± 6.2%
IG1: 7.7 ± 6.6%
IG2: 9.5 ± 6.8%
IG3: 6.3 ± 5%
[42] Europe(Spain) RCT ATPIII
n = 40
IG1: 20
IG2: 20
Women: 67%
Age: 50–66
3 NE
Diet, exercise
- Within groups:
IG1
IG2 (exercise)
- Between groups
YES/YES
p < 0.05
p < 0.05
p < 0.05
YES (%)/NO
p < 0.05
p < 0.05
p < 0.05
YES/NO
p < 0.05
p < 0.05
p < 0.05
YES/NO
p < 0.05
p < 0.05
NS
BW:
IG1: 5.38 kg
IG1: 6.23 ± (0.83)%
IG2: 8.38 kg
IG2: 8.45 ± (0.76)%
BF:
IG1: 2.76%
IG2: 4.5%
BMI:
IG1: 2.09 kg/m2
IG2: 3.26 kg/m2
WC:
IG1: 3.72 cm
IG2: 4.18 cm
[43]
North
America
(USA)
RCT ATP III
n = 21
IG1: 11
IG2: 10
Men: 52%
Age: 66.2 ± 1.1
3
Dual-x-ray absorptiometry
(DEXA; Lunar Prodigy,
Madison, WI); Height was
measured with a
wall-mounted stadiometer
and weight was recorded on
a digital scale in a
hospital gown
Diet, exercise
- Within groups:
IG1 (high glycemic diet)
IG2 (low glycemic diet)
- Between groups
YES/NO
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
NS
NO/YES
p < 0.05
p < 0.05
p < 0.05
BW:
IG1: 11 kg
IG2: 6.8 kg
BF:
IG1: 8.9 kg
IG2: 5.7 kg
BMI:
IG1: 3.6 kg/m2
IG2: 2.7 kg/m2
WC:
IG1: ~10%
IG2: ~6%
Int. J. Environ. Res. Public Health 2019, 16, 3481 12 of 31
Table 3. Cont.
Author(s)
[36–62]
Location Study
Design
MS Diagnosis
Criteria [1]
Sample/Groups/
Characteristics Studied
Duration
(months)
Body Composition
Measurement Instrument
Intervention
Method/Comparative Statistical
Analysis of the BC
Anthropometric Parameters and Measurement Unit
Analyzed (Statistical results) Decreases in Body Composition
Mean ± SD or Mean ± (SE) or
Mean (CI, 95%)BW (kg/%) BF (kg or %) BMI(kg/m2/%)
WC
(cm/%)
[44] Oceania(Australia) RCT IDF
n = 58
IG1: 20
IG2: 19
CG: 19
Men: 59%
Age: 55 ± 6
3
Dual-energy X-ray
absorptiometry (DXA,
GE-LUNAR Prodigy
Advance PA+130510, GE
Medical Systems, Lunar,
Madison, WI, USA)
Diet, exercise
- Within groups:
IG1 (diet)
IG2 (diet and exercise)
- Between groups:
IG1 vs. IG2
IG1 vs. CG
IG2 vs. CG
YES/NO
p < 0.001
p < 0.001
NS
p < 0.01
p < 0.01
YES/NO
p < 0.001
p < 0.001
NS
p < 0.01
p < 0.01
YES/NO
p < 0.001
p < 0.001
NS
p < 0.01
p < 0.01
YES/NO
p < 0.001
p < 0.001
NS
p < 0.05
p < 0.01
p < 0.01
BW:
IG1: 7.1 ± 2.9 kg
IG2: 8.7 ± 4.6 kg
BF:
IG1: 5.2± 3.0 kg
IG2: 7.0± 3.9 kg
BMI:
IG1: 2.4± 1.0 kg/m2
IG2: 2.9± 1.4 kg/m2
WC:
IG1: 6.7±3.2 cm
IG2: 10.0±5.2cm
[45]
North
America
(USA)
RCT
(parallel-arm) ATPIII
n = 32
IG1: 8
IG2: 9
IG3: 8
IG4: 7
Men: 100%
Age: 59 ± 7
3
Tanita BC-418 Segmental
Body Composition
Analyzer/Scale (Tanita Inc.
Tokyo, Japan), which has
been shown to correlate
strongly (r ≥ 0.95, p < 0.001)
with both whole-body and
regional composition values
obtained using the gold
standard, dual-energy X-ray
absorptiometry (DEXA)
Diet, exercise
- Within groups:
IG1 (low fat diet)
IG2 (low fat diet and exercise)
IG3 (carbohydrate-restricted diet)
IG4 (carbohydrate-restricted diet
and exercise)
-Between groups
NO/NO NO/NO NO/NO YES/NO
p < 0.01
p < 0.01
p < 0.01
p < 0.01
NS
WC:
IG1: 5 cm
IG2: 10 cm
IG3: 8 cm
IG4: 10 cm
[46]
South
America
(Brazil)
RCT ATPIII
n = 75
IG1: 25
IG2: 25
CG: 25
Men: 65%
Age: 30–55
12
Bioelectrical impedance
(Omron HBF 306
Bioimpedance Analyzer) and
WC was measured between
the last rib and the iliac crest
Diet, exercise
CG (high CH diet and exercise
recommendations)
- Within groups:
IG1 (low CH diet and walking)
IG2 (low CH diet and aerobic
exercise)
-Between groups
YES/NO
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
NS
BW:
IG1: 9 kg
IG2: 11 kg
CG: 8 kg
BF:
IG1: 3%
IG2: 3%
CG: 2%
BMI:
IG1: 2.9 kg/m2
IG2: 3.5 kg/m2
CG: 2.9 kg/m2
WC:
IG1: 14 cm
IG2: 14 cm
CG: 14 cm
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Table 3. Cont.
Author(s)
[36–62]
Location Study
Design
MS Diagnosis
Criteria [1]
Sample/Groups/
Characteristics Studied
Duration
(months)
Body Composition
Measurement Instrument
Intervention
Method/Comparative Statistical
Analysis of the BC
Anthropometric Parameters and Measurement Unit
Analyzed (Statistical results) Decreases in Body Composition
Mean ± SD or Mean ± (SE) or
Mean (CI, 95%)BW (kg/%) BF (kg or %) BMI(kg/m2/%)
WC
(cm/%)
[47] Oceania(Australia)
RCT
(parallel
group)
ATPIII
n = 38
IG1: 13
IG2: 13
CG: 12
Women: 100%
Age: 55 ± 1
3
DEXA scan (GE-LUNAR
Prodigy Advance
PAþ130510; GE Medical
Systems, Lunar, Madison,
Wisconsin, USA); BW, using
a digital scale. WC at the
midpoint between the lowest
rib and iliac crest, and hip
circumference at the level of
the greater trochanters
Diet, exercise
- Within groups:
IG1 (diet)
IG2 (diet and exercise)
- Between groups:
IG1 vs. IG2
IG1 vs. CG
IG2 vs. CG
YES/YES
p < 0.001
p < 0.001
p < 0.05
p < 0.01
p < 0.01
YES/NO
p < 0.001
p < 0.001
p < 0.005
p < 0.001
p < 0.001
YES/NO
p < 0.001
p < 0.001
NS
p < 0.01
p < 0.00
YES/NO
p < 0.001
p < 0.001
p < 0.01
p < 0.001
p < 0.001
BW:
IG1: 7.9 ± (0.8) kg
IG1: 8.2 ± (0.8)%
IG2: 10.4 ± (1.1) kgIG2: 10.7 ±
(0.8)%
BF:
IG1: 5.7 ± (0.9) kg
IG2: 8.5 ± (1.0) kg
BMI:
IG1: 2.7 ± (0.3) kg/m2
IG2: 3.4 ± (0.3) kg/m2
WC: IG1: 7.0 ± (0.8) cm
IG2: 10.9 ± (1.2) cm
[48]
North
America
(USA)
RCT ATPIII
n = 24
IG1: 12
IG2: 12
Women: 83%
Age: 25–80
3 NE
Diet, exercise
- Within groups:
IG1 (without interest, for the use
of supplementation)
IG2 (Mediterranean diet, exercise)
- Between groups
NO/YES
p < 0.01
p < 0.01
NS
NO/NO YES/YES
p < 0.01
p < 0.01
NS
NO/YES
p < 0.01
p < 0.01
NS
BW:
IG1: 6.8 ± (1.1)%
IG2: 5.2 ± (1.1)%BMI:
IG1:2.1 ± (0.3) kg/m2
IG1: 6.7± (0.9)%
IG2: 1.8 ± (1.1) kg/m2
IG2: 5.2 ± (1.1)%
WC:
IG1: 5.9 ± (1.1)%
IG2: 5.4 ± (1.1)%
[49] Oceania(Australia) RCT ATPIII
n = 59
IG1: 20
IG2: 20
CG: 19
Men: 59%
Age: 55 ± 1
3
Dual-energy X-ray
absorptiometry scan
(GE-LUNAR Prodigy
Advance PA+130510; GE
Medical Systems, Lunar,
Madison, WI); BW was
measured using a digital
scale and WC was measured
at the midpoint between the
lowest rib and iliac crest and
hip circumference at the
level of the greater
trochanters
Diet, exercise
- Within groups:
IG1 (diet)
IG2 (diet and exercise)
- Between groups:
IG1 vs. IG2
IG1 vs. CG
IG2 vs. CG
YES/YES
p < 0.001/NE
p < 0.001/NE
NS/NS
p < 0.01/NE
p < 0.01/NE
YES/NO
p < 0.001
p < 0.001
NS
p < 0.01
p < 0.01
YES/NO
p < 0.001
p < 0.001
NS
p < 0.01
p < 0.01
YES/NO
p < 0.001
p < 0.001
p < 0.01
p < 0.01
p < 0.01
BW:
IG1: 7.1 ± (0.6) kg
IG1: 7.6 ± (0.7)%
IG2: 8.4 ± (0.1) kg
IG2: 8.7 ± (0.9)%
BF:
IG1:5.2 ± (0.7) kg
IG2: 6.9 ± (0.9) kg
BMI:
IG1:2.4 ± (0.2) kg/m2
IG2: 2.8 ± (0.3) kg/m2
WC:
IG1: 6.7 ± (0.7) cm
IG2: 9.8 ± (1.2) cm
[50] Oceania(Australia) RCT ATPIII
n = 34
IG1: 15
IG2: 19
Men: 62%
Age: 55 ± 1
3 NE
Diet, exercise
- Within groups:
IG1 (exercise)
IG2
- Between groups
YES/NO
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
NS
NO/NO YES/NO
p < 0.001
p < 0.001
NS
BW:
All: 8.2 ± (0.7) kg
IG1: 8.4 ± (1.1) kg
IG2: 8.1 ± (0.9) kg
BF:
All: 6.4 ± (0.6) kg
IG1: 6.9 ± (1.1) kg
IG2: 6.0 ± (0.7) kg
WC:
All: 8.6 ± (0.8) cm
IG1: 9.8 ± (1.3) cm
IG2: 7.6 ± (0.9) cm
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Table 3. Cont.
Author(s)
[36–62]
Location Study
Design
MS Diagnosis
Criteria [1]
Sample/Groups/
Characteristics Studied
Duration
(months)
Body Composition
Measurement Instrument
Intervention
Method/Comparative Statistical
Analysis of the BC
Anthropometric Parameters and Measurement Unit
Analyzed (Statistical results) Decreases in Body Composition
Mean ± SD or Mean ± (SE) or
Mean (CI, 95%)BW (kg/%) BF (kg or %) BMI(kg/m2/%)
WC
(cm/%)
[51]
North
America
(USA)
RCT ATPIII
n = 24
IG1: 12
IG2: 12
Women: 62.5%
Age: 65.5 ± 5.0
3
Hydrostatic weighing, and
fat mass and fat-free mass
were estimated using the
equation of Siri
Diet, exercise
- Within groups:
IG1
IG2 (diet)
- Between groups
YES/NO
p < 0.001
p < 0.001
p < 0.05
YES/NO
p < 0.001
p < 0.001
NS
YES/NO
p < 0.001
p < 0.001
p < 0.05
YES/NO
p < 0.001
p < 0.001
NS
BW:
IG1: 3.7 ± 3.4 kg
IG2: 6.8 ± 2.7 kg
BF:
IG1: 6.0 kg
IG2: 4.5 kg
BMI:
IG1: 1.3 kg/m2
IG2: 2.4 kg/m2
WC:
IG1: 5.6 cm
IG2: 6.5 cm
[52]
North
America
(USA)
RCT
(parallel-arm) ATPIII
n = 47
IG1: 24
IG2: 23
Men: 50%
Age: 20–65
3
DXA (QDR-4500W; Hologic
Corp, Waltham, MA); BW by
electronic scale (model CN20;
Cardinal/Detecto, Webb City,
MO); WC was measured
according to guidelines of
the National Heart, Lung,
and Blood Institute (NHLBI)
Diet, exercise
- Within groups:
IG1 (without refined grain diet)
IG2 (refined grain diet)
- Between groups
YES/NO
p < 0.001
p < 0.001
NS
YES (%)/NO
p < 0.001
p < 0.001
NS
NO/NO YES/NO
p < 0.001
p < 0.001
NS
BW:
IG1: 3.7 ± 3.5 kg
IG2: 5.3 ± 5.2 kg
BF:
IG1: 1.2 ± 1.3%
IG2: 1.0 ± 1.6%
WC:
IG1: 2.5 ± 3.7 cm
IG2: 4.7 ± 6.4 cm
[53] Asia(Thailand) RCT IDF
n = 110
IG1: 52
IG2: 58
Women: 83%
Age: 42.5 ± 1.1
3
Body composition were
measured using BIA
(TANITA® BC-418, Tanita
corp., Tokyo, Japan). WC
was measured using a no
stretchable tape with
measurement taken at a
horizontal line midway
between the highest point of
iliac crest and the lowest ribs
Diet, intervention in lifestyle
Within
IG1: Lifestyle intervention
IG2: lifestyle intervention plus
meal replacement
Between groups:
YES/NO
p < 0.01
p < 0.01
p < 0.05
YES/YES
p < 0.01
p < 0.01
NS
YES/NO
p < 0.01
p < 0.01
p < 0.05
YES/NO
p < 0.01
p < 0.01
NS
BW:
IG1: 1.4 kg
IG1: 1.53%
IG2: 2.3 kg
IG2: 2.86%
BF:
IG1: 1.05 kg
IG1: 0.8%
IG2: 1.58 kg
IG2: 1%
BMIIG1: 0.49 kg/m2
IG2: 0.94 kg/m2
WC
IG1: 2.5 cm
IG2: 3.25 cm
[54] Asia(Iran) RCT ATPIII
n = 117
IG: 64
CG: 53
Men: 66.3%
Age: 44.2 (s.d. = 10.0)
6
BW by a calibrated scale
(Seca, Hamburg, Germany
model 8811021658) to the
nearest of 0.1 kg; Height by
stadiometer (Seca, Hamburg,
Germany) to the nearest of
0.1 cm
Diet, intervention in lifestyle
- Within groups:
IG (My Healthy Heart Profile
interactive web)
- Between groups
YES/NO
p < 0.001
p < 0.05
NO/NO YES/NO
p < 0.001
NS
NO/NO
BW:
IG: 4 kg
BMI:
IG: 1.2 kg/m2
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Table 3. Cont.
Author(s)
[36–62]
Location Study
Design
MS Diagnosis
Criteria [1]
Sample/Groups/
Characteristics Studied
Duration
(months)
Body Composition
Measurement Instrument
Intervention
Method/Comparative Statistical
Analysis of the BC
Anthropometric Parameters and Measurement Unit
Analyzed (Statistical results) Decreases in Body Composition
Mean ± SD or Mean ± (SE) or
Mean (CI, 95%)BW (kg/%) BF (kg or %) BMI(kg/m2/%)
WC
(cm/%)
[55] Europe(Greece) RCT ATP III
n = 47
CG: 13
IG1: 16
IG2: 18
Men: 57%
Age: 49.0 ± 11.8
6
Weight and height were
measured on a leveled
platform scale and a
wall-mounted stadiometer,
to the nearest 0.5 kg and 0.5
cm; WC was measured in the
middle between the 12th rib
and the iliac crest
Diet, intervention in lifestyle
CG (usual care)
- Within groups:
IG1 (face-to-face)
IG2 (telephone group)
- Between groups:
IG1 vs. CG
IG2 vs. CG
NO/NO NO/NO YES/NO
p < 0.001
p < 0.001
p < 0.001
p < 0.001
YES/NO
p < 0.001
p < 0.001
p < 0.001
p < 0.05
BMI:
CG: 0.1 ± 1.0 kg/m2
IG1: 1.4 ± 1.5 kg/m2
IG2: 1.2 ± 1.4 kg/m2
WC:
CG: 0.5 ± 4.4 cm
IG1: 4.1 ± 5.0 cm
IG2: 3.5 ± 4.4 cm
[56]
South
America
(Brazil)
RCT ATP III
n = 58
CG: 17
IG1: 21
IG2: 20
Women: 55.5%
Age: 30–59
3
Body weight measured,
using a properly calibrated
160 kg Cauduro scale; WC,
with a millimeter no
extensible long tape at the
abdomen’s maximum
extension
Diet, exercise, intervention
in lifestyle
CG: (standard intervention)
- Within groups:
IG1 (group intervention)
IG2 (individual intervention)
- Between groups:
IG1 vs. CG
IG2 vs. CG
IG1 vs. IG2
NO/NO NO/NO YES/NO
p < 0.01
p < 0.05
p < 0.05
p < 0.05
NS
YES/NO
p < 0.05
p < 0.05
p < 0.05
p < 0.05
NS
BMI:
IG1: 1.8 kg/m2
IG2: 1.5 kg/m2
WC:
IG1: 4.4cm
IG2: 5.3cm
[57] Europe(Spain) RCT IDF
n = 406
IG: 230
CG: 176
Men: 55%
Age: 18–80
36 NE
Diet, exercise, intervention
in lifestyle
CG: 176 (healthy diet with general
physical activity)
- Within groups:
IG (Mediterranean diet
and exercise)
- Between groups
YES/NO
NE
NS
NO/NO YES/NO
NE
NS
YES/NO
NE
p < 0.001
BW:
IG: increase
BMI:
IG: increase
WC:
IG: 0.3 ± 6.0 cm
[58] Europe(Germany)
RCT
(parallel-group)
groups
IDF
n = 178
CG: 60
IG1: 60
IG2: 58
Men: 57%
Age: 30–60
12 NE
Diet, exercise, intervention
in lifestyle
Within groups:
IG1 (monitored weekly)IG2
(monitored monthly)
- Between groups:
IG1 vs. IG2
IG1 vs. CG
IG1 vs. CG
YES/NO
p < 0.001
p < 0.001
p < 0.05
p < 0.001
p < 0.01
NO/NO YES/NO
p < 0.001
p < 0.001
p < 0.05
p < 0.001
p < 0.01
YES/NO
p < 0.001
p < 0.001
p < 0.05
p < 0.001
p < 0.05
BW:
IG1: 12.2 kg (8.8–10.5)
IG1: 11.4% (9.8–12.9)
IG2: 8.8 kg (7.1–10.4)
IG2: 8.6% (7–10.2)
BMI:
IG1: 4.1 kg/m2 (3.6–4.6)
IG2: 2.8 kg/m2 (2.3–3.4)
WC:
IG1: 14.3 cm (12.3–16.3)
IG2: 10.8 cm (8.9–12.8)
[59] Oceania(Australia) RCT ATP III
n = 66
IG: 31
CG: 35
Women: 68%
Age: 18–60
12
Tanita BC-418 segmental
body composition analyzer
(Tanita Corporation of
America Inc., Arlington
Heights, IL). WC was
measured midway between
the top of the iliac crest and
the most inferior part of the
rib cage
Diet, exercise, intervention
in lifestyle
IG: without interest, for the use of
the gastric balloon
- Within groups:
CG (diet and exercise)
YES/YES
p < 0.05
NO/NO YES/NO
NE
YES/NO
NE
BW:
CG: 5.3 kg
CG: 5.2%
BMI:
CG: 1.9 kg/m2
WC:
CG: 6.4 cm
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Table 3. Cont.
Author(s)
[36–62]
Location Study
Design
MS Diagnosis
Criteria [1]
Sample/Groups/
Characteristics Studied
Duration
(months)
Body Composition
Measurement Instrument
Intervention
Method/Comparative Statistical
Analysis of the BC
Anthropometric Parameters and Measurement Unit
Analyzed (Statistical results) Decreases in Body Composition
Mean ± SD or Mean ± (SE) or
Mean (CI, 95%)BW (kg/%) BF (kg or %) BMI(kg/m2/%)
WC
(cm/%)
[60] Europe(Greece) RCT ATP III
n = 88
CG: 29
IG1: 29
IG2: 30
Men: 57%
Age: 49.9 ± 10.8
6
BW and height were
measured on a levelled
platform scale and a
wall-mounted stadiometer
Diet, exercise, intervention
in lifestyle
- Within groups:
IG1 (healthy food)
IG2 (healthy food and decrease of
less healthy food)
- Between groups:
IG1 vs. CG
IG2 vs. CG
NO/NO NO/NO YES/NO
p < 0.05
p < 0.05
p < 0.05
p < 0.05
YES/NO
p < 0.05
p < 0.05
p < 0.05
p < 0.05
BMI:
CG: 0.1 ± 1.0 kg/m2
IG1: 1.2 ± 1.4 kg/m2
IG2: 1.2 ± 1.4 kg/m2
WC:
CG: 0.4 ± 4.4 cm
IG1: 3.5 ± 4.4 cm
IG2: 3.1 ± 4.0 cm
[61]
Asia
(South
Korea)
RCT ATPIII
n = 48
IG: 27
CG: 21
Women: 100%
Age: 62.7 ± 9.0
12
BW was measured with a
high-precision scale (InBody
220; Biospace company,
Seoul, Korea); WC was
measured midway between
the lowest rib and the
iliac crest
Diet, exercise, intervention
in lifestyle
- Within groups:
IG
- Between groups
YES/NO
p < 0.001
p < 0.001
NO/NO YES/NO
p < 0.001
p < 0.001
YES/NO
p < 0.001
p < 0.001
BW:
IG: 4.3 kg
BMI:
IG: 1.4 kg/m2
WC:
IG: 9.4 cm
[62]
Asia
(South
Korea)
RCT ATPIII
n = 29
IG: 16
CG: 13
Women: 100%
Age: 66.7 ± 9.7
1
BW was measured with a
high-precision scale
(GM1000; Neo GMTEC,
Seoul, Korea); WC was
measured midway between
the lowest rib and the
iliac crest
Diet, exercise, intervention
in lifestyle
- Within groups:
IG
- Between groups
YES/NO
p < 0.001
p < 0.001
NO/NO YES/NO
p < 0.001
p < 0.001
YES/NO
p < 0.001
p < 0.001
BW:
IG: 4.6 kg
BMI:
IG: 2 kg/m2
WC:
IG: 6.2 cm
Body weight (BW); body fat (BF); body mass index (BMI); waist circumference (WC); control group (CG); intervention group (IG); non-significant (NS); the information is not available in
the clinical trial evaluated (NE); randomized controlled trial (RCT); YES: the article includes the analysis of the parameter expressed in its correspondent units; NO: the article does not
include the analysis of the parameter; carbohydrate (CH); mono or poly-unsaturated fatty acids (MUFA, PUFA); first aerobic interval training, later diet (EXER-then-DIET); exercise
and diet simultaneously (EXER + DIET); 18% proteins, mostly of vegetable origin, 55% carbohydrate and 27% fat (M-DASH); 18.4% proteins, highest proportion of animal origin, 54%
carbohydrate and 27% fat (BOLD); 27% proteins, highest proportion of animal origin, 45% carbohydrate and 27% fat (BOLD+); physical exercise performed at a moderate height of 1700 m
(moderate altitude exercise); exercise at sea level to 200 m (sea level exercise).
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3. Results
3.1. Search Features and Types of Interventions Identified
A total of 2684 articles were identified, but finally only 1.6% of the overall were included on the
basis on the search strategy (Figure 1). The most useful strategy search included the following variables:
“metabolic syndrome” and “weight loss” or “weight reduction” or “fat loss” or “fat reduction” or
“lifestyle” and “exercise” or “physical activity” or “sport” or “weightlifting”; Web of Science and
PubMed are the databases that had the most clinical trials included (Table 1). After analyzing the
items, they were classified into two groups according to the type of intervention used: exclusive
intervention (27%, Table 2) and multidisciplinary interventions (73%, Table 3). The most relevant
characteristics of the clinical trials included are (Tables 2 and 3): number of patients from 21 to 406
(median, 49 patients); greater proportion of mixed samples (75.7%), 8.1% only constituted by men and
16.2% only constituted by women; patients from 18 to 80 years old; sample groups located in Europe
(35.1%), America (29.7%), Asia (18.9%) and Oceania (16.2%); Adult Treatment Panel III (ATPIII) of
the National Cholesterol Education Program (NCEP), International Diabetes Federation (IDF), World
Health Organization (WHO) and The Examination Committee of Criteria for “Metabolic Syndrome”
in Japan as MS diagnosis criteria; temporary duration of the studies from 0.75 to 36 months (median
and mode 3 months, up to 6 months, 81.1%). The most abundant intervention modalities observed
were diet, physical exercise and/or changes in lifestyle (a combination of diet and physical exercise
predominates as intervention (45.9% of the studies)).
Regarding the ten works based on exclusive interventions, the duration of the interventions in
eight of them ranged from 2.5 to 6 months and just one had a duration up to 24 months. The sample
size ranged from 27 to 173 patients (median, 93.5 patients). Eight of them assigned the patients into two
groups (two intervention groups in five works and an intervention group together with a control group
in the others three). In the two remaining works, the patients were assigned into two intervention
groups and a control group. Concerning to the method of intervention, there were three works with
modifications in lifestyle, four impinged changes in diet and three controlled the method of exercise.
Regarding the twenty-seven articles based on multidisciplinary interventions, the duration in the
interventions ranged from 0.75 to 36 months (77.8% with a period up to 6 months; five and one with
durations of 12 and 36 months, respectively). The sample size ranged from 21 to 406 patients (median,
48 patients). Fourteen of them assigned the patients into two groups (two intervention groups in
nine works and an intervention group together with a control group in the others five). Eleven works
designated three groups (nine studies with two intervention groups and a control group) and finally,
there were two works with four intervention groups. Concerning the methods of intervention, there
were seventeen works with interventions on diet and exercise and ten with modifications in diet,
exercise and lifestyle.
3.2. The Most Significant Body Composition Changes in MS (Tables 2 and 3)
As a response to the first secondary objective, the analysis reveals that multidisciplinary
interventions report the greatest changes in body composition. In this context, Luley and co-workers
show the largest changes in BW, BMI and WC [58]. This was a 12-month multidisciplinary intervention
in diet, exercise and lifestyle, carried out in Europe with a sample of 178 patients (mainly men, 57%)
between 30 and 60 years of age, randomized in a control group and two intervention groups. All the
subjects were advised to increase their usual daily physical activity following Magdeburg Dual Diet
(500 kcal per day and low in carbohydrates, preferably with a low glycemic index). Diet and exercise
were monitored in IG1 weekly by letter, in IG2 monthly by telephone, whereas CG was not monitored.
The changes of each variable measured was: 12.2 kg (CI 95%, 10.5–13.8), (11.4% (9.8–12.9)), 4.1 kg/m2
(3.6–4.6) (12%) and 14.3 cm (12.3–16.2) (12.1%) in IG1 for BW, BMI and WC, respectively.
The Malin and Bonfanti clinical trials, based on multidisciplinary intervention techniques, show
the best results for reducing BF [39,43]. On the other hand, the clinical trial of Bonfanti and coworkers is
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a 3-month European study involving patients of both sexes, over 50 years old (n = 36) and randomized
in four intervention groups [39]. In two groups, the subjects followed hypocaloric diets with different
proportion in carbohydrates, protein and fats and in the remaining groups exercise was also added.
Subjects in IG1 followed a Mediterranean diet while subjects in IG2 followed a low fat diet rich in
complex carbohydrates. In IG3 and IG4, the respective diets of IG1 and IG2 were combined with
aerobic exercise. The change of BF was 12% in IG4.
It was analyzed whether the included clinical trials that have obtained the greatest variations in
body composition have developed the items recommended by the CONSORT method [63]. Between the
studies here included the following three have reported the highest number of positives results: Luley
et al., Malin et al. and Bonfanti et al. (59.4%, 37.84% and 35.2%, respectively) [39,43,58].
As a response to the second secondary objective, energy restriction in diet was a common
characteristic of the clinical trials that achieved the greatest changes in body composition in this review,
occasionally combined with structured physical exercise.
3.3. Anthropometric Parameters and Units of MS Changes in Body Composition Measurements (Tables 2 and 3)
With regard to the articles based on exclusive interventions, all of them study and report a
statistically significant (p-value <0.05) changes in BW within the intervention groups (final vs. baseline
levels), with the exception of an intervention group in which no significant differences in BF, BMI and
WC were observed [32]. Regarding to the differences in BW between intervention groups, they turned
out to be statistically significant in 50% of the total studies (Figure 2a).
In the case of BF, 50% of the works had results expressed in kg or percentage. Only one of them
presented statistically significant differences between the analyzed groups. On the other hand, nine of
the ten trials studied the changes in BMI in kg/m2, obtaining statistically significant changes among
groups in five of the nine studies. Finally, the loss of cm in WC was collected in all the works, reporting
statistically significant changes in four of the ten trials.
Concerning multidisciplinary intervention trials (Figure 2b), 85.2% of them included the study of
BW changes in kg or/and relative units. All but three of the trials studied and reported a statistically
significant (p-value <0.05) changes in BW (kg or relative units) within the intervention groups (final vs.
baseline levels), except in [36,37,39]. Related to the differences in BW between intervention groups,
they turned out to be statistically significant (p-value <0.05) in 52.2% of the cases (Figure 2b).
The variable BF was not included in 44.4% of the works analyzed, neither in absolute terms (kg
or %) nor in relative units. Fourteen studies reported significant differences within the intervention
groups but eight studied reported non-significant differences between the intervention groups.
Concerning BMI, twenty-one works included the study of the changes in absolute units and one of
them incorporates their study in relative units. Among these articles, twelve had significant differences
between groups. Finally, the loss in WC (in cm) was collected in 88.9% of the works, registering
statistically significant changes in twelve of the twenty-four trials. The study of the relative changes
appeared in three studies, with statistically significant differences between intervention groups in one
of them.
In order to reach the last secondary objective of this review, from all the articles selected it is
possible to conclude that the most analyzed parameter was WC (88.9% of the trials), followed by
BW (85.2%), BMI (77.8%) and BF (55.6%). Regarding WC, 44.4% of the articles reported statistically
significant differences among groups, 37% reported non-significant differences and 7.4% did not specify
the classification of the differences. In the case of BW, BMI and BF the percentages were 44.4%, 33.3%
and 7.4%, 44.4%, 29.6% and 3.7% and 18.5%, 29.6% and 7.4%, respectively (Figure 2c).
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4. Discussion
Due to the high rates of MS worldwide [5–7] and the fact that the guidelines for MS interventions
are scarce and old (dietary and physical exercise interventions) [64–66], it is necessary to delve into
which practical guidance would report a greater variation of body composition. In order to reach the
fourth secondary objective, Tables 4 and 5 were done [67–74] (European Guidelines and institutional
guides such as: AACE, ADA, ACE, AHA, NHLBI). The selected guides had to meet the following
criteria: to have a degree of evidence analysis; the main objective was to cause changes in body
composition; review articles would have been published in journals indexed in the Journal Citation
Reports (Web of Science) between 2005 and 2018.
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Table 4. Guidelines and consensus on the treatment of overweight, obesity, type 2 diabetes mellitus and metabolic syndrome: adults †.
Author [67–74] Recommendations in Dietary Intervention and Exercise
A
A
C
E/
A
C
E
[67]
Dietary intervention: energy reduction† and several types of diets stated with indications for different macronutrients (section algorithm: lifestyle
therapy); reducing total energy (caloric) intake should be the main component of any weight-loss intervention (grade A; BEL 1); even though the
macronutrient composition of meals has less impact on weight loss than adherence rates in most patients. In certain patient populations, modifying
macronutrient compositions may be considered to optimize adherence, eating patterns, weight loss, metabolic profiles, risk factor reduction, and/or
clinical outcomes (grade A; BEL 1).
Physical exercise: recommendations†; resistance training should be prescribed to patients with overweight or obesity undergoing weight-loss therapy
to promote fat loss while preserving fat-free mass; involvement of an exercise physiologist or certified fitness professional in the care plan should be
considered to individualize the physical activity prescription and improve outcomes (grade A; BEL 1).
Behavior interventions: lifestyle therapy in patients with overweight or obesity should include behavioral interventions that enhance adherence to
prescriptions for a reduced-calorie meal plan and increased physical activity; behavioral lifestyle intervention and support should be intensified if
patients do not achieve a 2.5% weight loss in the first month of treatment, as early weight reduction is a key predictor of long-term weight-loss success
(grade A; BEL 1).
Degrees of evidence: Origin from American Association of Clinical Endocrinologists 2010 [68].
O
ve
rw
ei
gh
ta
nd
O
be
si
ty
Eu
ro
pe
an
G
ui
de
li
ne
s
[69]
Dietary intervention: energy reduction† (evidence, grade A, B); VLCDs† are unsuitable as a sole source of nutrition for children and adolescents,
pregnant or lactating women and the elderly (level 2); the combination of exercise with caloric restriction helps in reducing body weight and body fat
and preserving FFM, as compared to diet alone (level 1; grade B)
Physical exercise: recommendations† (level 2; grade B)
BW: A decrease of 5–15% over a period of 6 months is realistic and of proven health benefit (evidence, level 1)†
Levels and degrees of evidence. Origin: [70].
T
2D
M
A
D
A
[71]
Dietary intervention: energy reduction†
Physical exercise: recommendations† (grade B)
BW: in overweight and obesity with T2DM, a sustained reduction of 5%, improves glycemic control and reduces the need for glucose-lowering drugs; in
obese patients with T2DM, weight loss >5% produces benefits in the control of blood glucose, lipids and blood pressure
A
A
C
E/
A
C
E
[72]
Lifestyle therapy: the key components are medical nutrition therapy, regular physical activity, enough hours of sleep (6–9 h), behavioral support,
smoking cessation and avoidance of all tobacco products (this component should be left for the end of the intervention) (see Integral algorithm for the
management of type 2 diabetes, prediabetes and obesity). Coulston and his colleagues present another approach in the definition of “medical nutrition
therapy” [73].
M
S [74]
Dietary intervention and physical exercise: recommendations †
BW: 7–10% reduction of body weight in a period of 6 to 12 months and achieve an ideal BMI < 25 kg m−2
A
H
A
/N
H
LB
I
[64]
Dietary intervention: reduction of intake of saturated fat, trans fat, cholesterol
Physical exercise: recommendations†
BW: 7–10% during the 1 year of therapy, continue with the goal of achieving a desirable weight (BMI < 25 kg m−2)
† Extensive information is given in Table 5. American Association of Clinical Endocrinologist (AACE); American College of Endocrinology (ACE); American Diabetes Association (ADA);
American Heart Association (AHA); best evidence level (BEL); is recommended for all people with prediabetes or DM, including T1D, T2D, GDM, and other less common forms of DM.
MNT must be individualized, generally via evaluation and teaching by a trained nutritionist or registered dietitian or a physician knowledgeable in nutrition (Medical Nutrition Therapy);
National Heart, Lung, and Blood Institute (NHLBI); Scottish Intercollegiate Guidelines Network (SIGN); type 2 diabetes mellitus (T2DM);very low energy density diets (VLCD); kilograms
(Kg); percentage (%); body weight (BW); minutes (min); month (mo); week (wk); pounds (lb).
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Table 5. Intervention strategies in the decrease of body composition, in overweight, obesity, type 2 diabetes mellitus and metabolic syndrome.
Dietary Intervention
Energy Density Restriction/Energy
Density recommends
Overweight and obesity ±500–750 kcal day−1 [66]; ± 600 kcal day−1 [69]; 800–1200 kcal day−1 [69]
T2DM ±500–750 kcal day−1 [2017 [71]]/1200–1500 kcal day−1 in women and
1500–1800 kcal day−1 in men [71]
MS Reduction of 500–1000 kcal day−1 [74]
VLCD
Overweight and obesity <800 kcal day−1 [69]
T2DM and MS ND
Macronutrients and diets
Overweight and obesity
Different amounts of macronutrients (hydrates, proteins and fats) and
giving rise to different types of diets [66]; hypocaloric balanced diets result
in clinically significant weight loss independent of macronutrients [69]
T2DM and MS
Recommended diets may differ in advising foods high in fat or in
hydrates; the recommendation for consumption of recommended foods
does not differ: whole grains, vegetables, fruits, legumes, low-fat dairy
products, lean meats, nuts and seeds; it is recommended to adapt the diet
to the health status and the preferences of the patient [64,71,74]
Physical Exercise
Overweight and obesity Aerobic exercise > 150 min wk
−1 (3 to 5 days wk−1) [67]; moderate aerobic
exercise: 150 min wk−1 (energetically walking) [69]
T2DM
Greater than or equal to 150 min of physical exercise a week at moderate
intensity, 3 days a week at least; In the US Department of Health, does not
differentiate between indications for T1DM and T2DM [71]; 150 min wk−1
moderate effort; strength training and increase according to each
individual [72]
MS
≥30 to 60 min of exercise (moderate intensity on most days of the week,
according to each individual) [74]; ≥30 min from 5 days wk−1 continuous
or intermittent (and preferably ≥60 min and moderate intensity) [64]
Metabolic syndrome (MS); minutes (min); not stated (ND); type 1 diabetes mellitus (T1DM); type 2 diabetes mellitus (T2DM); week (wk).
Int. J. Environ. Res. Public Health 2019, 16, 3481 22 of 31
The reasoning of using the most appropriate practical guidance for obesity and T2DM in order to
address the lack of knowledge in MS is: the appearance of abdominal obesity is the most frequent in
this syndrome [13,75–77], and the known relationship of developing this syndrome at the same time
as diabetes [14,15,78]. With all this in mind and as result of this work, the following advices for the
design of efficient interventions in adults with MS are proposed:
To obtain the greatest changes produced in body composition, it is recommended multidisciplinary
interventions (Tables 2 and 3) and Table 4 indicates 5 factors that should be intervened: medical
nutrition therapy, regular physical activity, sleeping between 6 and 9 h sleep, limiting alcohol intake to
moderate, and cessation of smoking (at the end of the procedure).
Several options have been identified in the energy constraint to be applied to dietary intake:
40% energy reduction progressively [39] or a restriction of 500 kcal day−1 [58] (Table 3) vs. restriction of
1000 kcal day−1 and energy intake (1200–1500 kcal day−1 in women and 1500–1800 kcal day−1 in men)
(Table 5). Considering all the reports’ approaches, we suggest a restriction between 500 and 1000 kcal
day−1. The nutritionist should be cautious in the degree of energy restriction that is prescribed and
adapt to the individualization of each subject, because there are different tolerances to fasting situations.
Individuals with insulin-resistant excess weight compared with thin subjects have metabolic inflexibility
(they did not register this adaptation to use fuel for the oxidation of fatty acids). This inflexibility is
associated with several pathologies (metabolic syndrome, diabetes mellitus type 2 and cancer) and
several factors such as: composition of the diet, frequency of ingestion, physical exercise and the use of
certain pharmacological compounds [79,80].
Two options are presented in the distribution of macronutrients: (i) 55–58% carbohydrates, less
than 30% fat and 15–22% proteins [39,43]; (ii) low in carbohydrates with a low glycemic index [58]
(Table 3) vs. advices summarized in Table 5.
Aerobic exercise between 65–85% intensity daily (maximum heart rate) is recommended [39,44]
(Table 3) vs. guidelines (Table 5) which recommend 150 min wk−1 (minutes per week) (3 to 5 days wk−1)
and introduces strength training. The prescription for physical exercise must be structured (Table 5) [22].
The concepts of structured physical exercise were identified by the American College of Sports
Medicine [81].
The reduction of 5% of body weight is advised, which will lead to improvements in metabolic
alterations [30,82]. Despite the above, it would be more advisable to indicate the variation of 5% of
body fat instead, in subjects with obesity and/or MS. This limit would be valid for the following cases:
(i) subjects performing physical exercise, for the increase of muscle mass affecting body weight; (ii) for
the reduction of subjects with low excess weight or fat (overweight and/or high fat level); (iii) and to set
an accessible target for subjects with higher excess weight and fat (obesity and very high fat level) [83].
On the other hand, the following complementary advices are also established:
To follow the guidelines for the design of randomized trial reports [63] and other randomized
guides [84].
The nutritionist involved should be the manager of the design of the dietetic intervention [71,85,86].
To incorporate body composition measuring devices for clinical and research use on MS [86,87].
The following anthropometric parameters should be used for the calculation of metabolic risk: fat
mass index (fat mass height−2), waist circumference, abdominal diameter and body weight [19–22].
The main predictor of adverse metabolic events is visceral adipose tissue [75,76,88,89].
The tools used for evaluation of the nutritional condition at the beginning and in its follow-up
must be described as follows.
a. The available procedures must be identified to recognize in what type of patients and in what
moment they must be applied. The variation in the use of the procedures can be due to factors as:
ethnic groups, age, gender and physical limitations (in case of the use of crutches, prothesis and/or
wheelchair or even in patients without toes due to amputations because of the diabetes) [71,86].
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b. The use of distance or remote health care is recommendable: (i) when the patient does not reside
in the same population of the center of health and/or hospital [86]; (ii) in case of older people
or specific cases in which the patients find hard to attend themselves to the center [86]; (iii) in
coaching strategy [90,91].
c. Monitoring of physical exercise and/or daily physical activity is recommended (triaxial
accelerometers) [92].
d. It is recommended to extrapolate the concept “obesogenic” for MS patients. This concept was
firstly used in 1996 (“obese” means excess of corporal fat and “genic” refers to production
or synthesis) [93]. Currently, the obesogenic environmental is defined as “the addition of the
influences that have the environments, the opportunities or the living conditions to promote the
obesity in individuals or populations” [94]. These influences promote the consumption of high
levels or energy as well as diets based on non-healthy food (fast food, take away meals, etc.) [95].
e. Coaching is highly recommended as part of the design of further clinical trials with MS patients.
In the coaching per pairs approach during interventions of overweight, obesity and diabetes
patients, several instructed patients are selected to accompany and monitor to other patients
suffering the same pathology. Some recent studies have revealed that thanks to the coaching per
pairs approach, the levels of glycosylated hemoglobin, cholesterol, LDL, blood pressure, corporal
mass index (CMI), relation waist—hip, selfcare activities in the case of diabetes, depression and
other quality life factors are positively modified [90,91,96,97].
f. The nutritionist should be focused on “how” the patient or the family can apply the
recommendations given by professionals. The intervention must be considered not only for
the professional but also for the patient as a dynamic process, in which it will be necessary to
overcome unforeseen challenges [86,98].
As a new contribution, the authors of this work extrapolate the theory of the training cycle program
of an athlete to the terminology in this process of learning how to apply to lifestyle modification,
improving theoretical and practical applications [99,100]. The learning system of the improvement of
the alimentary habits must turn into a learning in the modification of the style of life (diet and exercise).
In this system, three periods or blocks are differentiated (initiation, improvement and maintenance)
(Table 6).
The professional should locate a subject in one period or another as follows. In the initiation period,
three cases could be possible: (a) The treatment has just begun; (b) the patient is reincorporated to this
period because they have increased body fat in several consecutive consultations; (c) the patient rejoins
because the treatment was previously abandoned. Advancing or remaining in the improvement period
occurs in two cases: a) they are in the initiation stage and body fat is decreasing regularly until there is
a considerable decrease (≥5%), depending on each case; (b) the patient rejoins after the maintenance
period because for personal reasons the treatment was paused at this stage. They will advance or
remain in the maintenance period in the event that they have assimilated the recommendations to
modify your lifestyle and is aware that they should not return to the previous habits in order not
to relapse into the variation of body fat, having or not having reached healthy body fat level (≥10%,
cumulative of the initiation and improvement stage), depending on each case [86].
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Table 6. Theory of the extrapolation of training cycle programs to the modification of lifestyle changes in metabolic syndrome with goals of body composition.
Lifestyle Modification
Program [72] Duration
Body Composition vs.
Duration [83,98] Comments [86]
Initial Assessment and
Monitoring Questionnaires
Multiannual Several years (2–4 years) Must depend on excess of weight(corresponding to body fat).
In this program, the subject may
evolve from one stage to another
(initiation, improvement
or maintenance).
Activity or exercise
measurement: Triaxial
accelerometers are
recommended [92]
Food ingestion [101,102]
Alcohol consumption [103]
Macrocycle Several months Considerable reduction in body fat perstage (≥ 5%).
Each macrocycle must be identified
by one stage, therefore one year may
have several macrocycles.
To apply questionnaires or
measuring instruments as much
as necessary
Mesocycle Several weeks
Objectives of body fat variation should
initially be measured by the kilos, but
over time, the percentage should be
used as the most recommended unit
of measure
Weekly planning: a. variation in
energy intake, macronutrients; b. in
physical exercise (Table 5) [81]; c.
sleep quality; d. alcohol
consumption.
Microcycle Several days It is not recommended to use bodycomposition measuring instruments.
It is important to measure dietary
intake, physical exercise
characteristics (Table 5), sleep hours
and alcohol consumption (extra
caloric intake)
Routine of one or more
consultation sessions Several hours and minutes
The evolution of body composition,
body fat and other anthropometric
parameters will be analyzed.
A break in training lasting more than
40 min qualifies as two
separate workouts.
Extrapolation [99,100].
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5. Conclusions
The discrepancies found in the recommendations reported in previous works indicate that more
research is required in this area of knowledge. From this systematic review, it can be concluded that
the best anthropometric parameters and units of measurement to monitor the interventions are those
related to dietary and physical exercise interventions. Besides, new practical guidance and advices
are introduced in order to improve further clinical interventions. Thus, this systematic review will
help with daily clinical practice in public health, sport sciences, nutrition and dietetics as well as
endocrinology and metabolism, because the practical guidance here proposed guarantee the best results
in changes of body composition, being easy to implement in daily practice in the consultation. It will
therefore help the professional and patient to identify easily and quickly how the treatment should
develop and what characteristics it should have. In addition, they are practical advices established
based on studies in which the best results are obtained in terms of changes in body composition.
The implementation of practical advices will help the public health on a large scale if the decrease of
the body composition also diminishes the metabolic alterations (thus lowering the cost of healthcare).
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